Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Anamorelin, the world's first oral drug specifically for the treatment of cancer cachexia, was launched by Ono Pharmaceutical of Japan in 2021. It helps patients regain their a···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：314
Koselugois a small molecule drug inhibitor targeting the MEK signaling pathway, and its core utility is focused on specific neurofibromas and has demonstrated excellent therapeutic···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：281
Koselugois a small molecule inhibitory drug targeting the MEK signaling pathway, and its core efficacy is reflected in its specific effect on specific neurofibromas, by blocking th···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：312
Koselugo, as a small molecule blocker of the MEK signaling pathway, has a core effect on specific neurofibromatosis by inhibiting the growth and proliferation mechanism of tumor ce···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：368
Koselugo is a small molecule inhibitor targeting the MEK signaling pathway, mainly used to treat specific types of neurofibromatosis, by blocking the growth and proliferation of tu···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：341
Koselugo is a small molecule inhibitor targeting MEK, which plays the role of a blocker on the mitogen activation link, and its core efficacy is reflected in the inhibition of MEK ···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：308
Koselugo is a small molecule MEK inhibitor and a repressor of mitogen activation, and its core role is to inhibit the activation of MEK signaling pathways, thereby effectively inte···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：322
Koselugois a small molecule MEK inhibitor (mitogen activation inhibitor), and its main mechanism of action is to block the growth and proliferation of tumor cells by inhibiting the···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：264
The therapeutic effect of Mitotane is aimed at adrenal cortical carcinoma, hyperplasia, and tumor-induced cortisolism without surgical options, and is characterized by fine regulat···【more】
Article source：Captain MedicineRelease date：2024-08-20Recommended：333
Anamorelin is the first drug specifically for the treatment of cachexia launched in Japan in 2021, which stimulates appetite by mimicking ghrelin; As a ghrelin receptor agonist, it···【more】
Article source：Captain MedicineRelease date：2024-08-20Recommended：251
In 2021, Japan launched Anamorelin, the world's first drug specifically for the treatment of cachexia. By mimicking the effects of ghrelin, the patient's appetite and body ···【more】
Article source：Captain MedicineRelease date：2024-08-20Recommended：345
Anamorelin is the world's first drug specifically for the treatment of cachexia, which increases appetite and improves body weight and muscle mass by activating ghrelin recepto···【more】
Article source：Captain MedicineRelease date：2024-08-20Recommended：328
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4442025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6302024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：852026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：4132025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4292025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4152025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4732025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3832025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
